Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin ophthalmic - Allergan

Drug Profile

Ciclosporin ophthalmic - Allergan

Alternative Names: Cyclosporin - Allergan; Cyclosporin ophthalmic emulsion; Cyclosporine - Allergan; RESTASIS; Restasis; RESTASIS MULTIDOSE; Restasis X; Restaysis

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Allergan
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Dry eyes

Most Recent Events

  • 20 Jul 2018 The US Court of Appeals for the Federal Circuit affirms the decision of the US Patent Trial and Appeal Board filed against Allergan by Mylan for patent disputes in USA
  • 07 Jun 2018 Launched for Dry eyes in North America (Ophthalmic) prior to June 2018
  • 07 Jun 2018 Allergan plans to launch the multi-dose preservative-free (MDPF) formulation of cyclosporine ophthalmic emulsion 0.05% (RESTASIS MULTIDOSE™) in Canada in September 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top